Tivic Health Systems (Tivic Health Systems) ROCE % : -183.88% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Tivic Health Systems ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Tivic Health Systems's annualized ROCE % for the quarter that ended in Dec. 2023 was -183.88%.

Tivic Health Systems ROCE % Historical Data

The historical data trend for Tivic Health Systems's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tivic Health Systems ROCE % Chart

Tivic Health Systems Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-156.18

-244.84

-94.81

-113.37

-212.69

Tivic Health Systems Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial										-177.25	-177.72	-189.65	-149.11	-183.88

Tivic Health Systems ROCE % Calculation

Tivic Health Systems's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-8.245	/	( ( (5.875 - 1.878)	+	(5.157 - 1.401) )	/ 2 )
	=	-8.245	/	( (3.997	+	3.756)	/ 2 )
	=	-8.245	/	3.8765
	=	-212.69 %

Tivic Health Systems's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-8.976	/	( ( (7.007 - 1)	+	(5.157 - 1.401) )	/ 2 )
	=	-8.976	/	( ( 6.007	+	3.756 )	/ 2 )
	=	-8.976	/	4.8815
	=	-183.88 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Tivic Health Systems (NAS:TIVC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Tivic Health Systems ROCE % Related Terms

Thank you for viewing the detailed overview of Tivic Health Systems's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Tivic Health Systems (Tivic Health Systems) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Tivic Health Systems Inc (NAS:TIVC) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

25821 Industrial Boulevard, Suite 100, Hayward, CA, USA, 94545

Website

https://www.tivichealth.com

Tivic Health Systems Inc is a health technology company focused on developing and commercializing non-invasive bioelectronic medicine. The company's platform-based technology activates the body's own healing mechanisms and can be programmed to treat various disease conditions. company's products provide a natural alternative to the standard synthetic chemical methods used by the pharmaceutical industry. ClearUP Sinus Relief, is a first commercial product of the company which is a patented handled device that uses ultra-low current electrical waves to relieve sinus pain and congestion symptoms that are prevalent in nasal allergies, sinus infections, chronic sinusitis, cold and flu and other disease conditions.

Executives

Sheryle Bolton	director	55 ALMADEN BLVD, SAN JOSE CA 95113
Dean Zikria	director	C/O INTUITY MEDICAL, INC., 3500 WEST WARREN AVENUE, FREMONT CA 94538
Jennifer Ernst	director, officer: Chief Executive Officer	750 MENLO AVENUE, SUITE 200, MENLO PARK CA 94025
Blake Gurfein	officer: Chief Scientific Officer	750 MENLO AVENUE, SUITE 200, MENLO PARK CA 94025
Ryan Sabia	officer: Chief Operating Officer	750 MENLO AVENUE, SUITE 200, MENLO PARK CA 94025
Kimberly Ann Bambach	officer: Interim CFO	25821 INDUSTRIAL BLVD., SUITE 100, HAYWARD CA 94545
Karen Drexler	director	C/O DIADEXUS, INC., 343 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Veronica Cai	officer: Chief Financial Officer	C/O CATALYST BIOSCIENCES, INC., 611 GATEWAY BOULEVARD, SUITE 710, SOUTH SAN FRANCISCO CA 94080
John Claude	10 percent owner	750 MENLO AVENUE, SUITE 200, MENLO PARK CA 94025
Briana Benz	officer: Chief Financial Officer	750 MENLO AVENUE, SUITE 200, MENLO PARK CA 94025